Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Siltuximab - EUSA Pharma

Drug Profile

Siltuximab - EUSA Pharma

Alternative Names: Anti-interleukin-6 monoclonal antibody - Centocor; cCLB8; Chimeric anti-interleukin-6 monoclonal antibody - Centocor; CNTO-328; Sylvant

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Biotech
  • Developer Centocor; Janssen Biotech; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant lymph node hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant lymph node hyperplasia
  • Phase II Multiple myeloma
  • No development reported Paraproteinaemia
  • Discontinued Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 24 Sep 2019 Janssen completes a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, France, Germany, Greece, Hungary, the Netherlands, Poland, Portugal, Romania, Russia, Slovakia, Spain and the United Kingdom (NCT00401843)
  • 09 Jan 2019 EUSA Pharma acquires siltuximab from Janssen Biotech
  • 09 Jan 2019 EUSA Pharma plans to re-launch siltuximab for Giant lymph node hyperplasia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top